MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Director Purchases $49,999.50 in Stock

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA - Get Free Report) Director Stan Smith bought 33,333 shares of the business's stock in a transaction dated Tuesday, June 3rd. The shares were acquired at an average cost of $1.50 per share, for a total transaction of $49,999.50. Following the transaction, the director now directly owns 1,305,059 shares in the company, valued at approximately $1,957,588.50. This represents a 2.62% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website.

MAIA Biotechnology Stock Down 8.2%

MAIA traded down $0.16 during trading on Friday, hitting $1.79. 231,876 shares of the stock were exchanged, compared to its average volume of 222,845. MAIA Biotechnology, Inc. has a 1-year low of $1.40 and a 1-year high of $4.31. The stock has a fifty day moving average price of $1.78 and a two-hundred day moving average price of $2.07. The firm has a market capitalization of $46.83 million, a P/E ratio of -1.30 and a beta of 0.20.

Institutional Investors Weigh In On MAIA Biotechnology

An institutional investor recently bought a new position in MAIA Biotechnology stock. Jane Street Group LLC purchased a new position in MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 39,057 shares of the company's stock, valued at approximately $77,000. Jane Street Group LLC owned 0.15% of MAIA Biotechnology at the end of the most recent reporting period. Institutional investors own 5.65% of the company's stock.

MAIA Biotechnology Company Profile

MAIA Biotechnology, Inc, a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer.